Literature DB >> 20482675

The biologic importance of tumor-infiltrating lymphocytes.

F Stephen Hodi1, Glenn Dranoff.   

Abstract

Detailed pathologic analysis has delineated a close association between intratumoral CD 8(+) cytotoxic T cells and favorable clinical outcomes in diverse cancers. Conversely, the presence at tumor sites of negative immune regulatory elements, such as FoxP 3(+) T cells (Tregs) and PD-1/PD-L1 co-stimulatory molecules, is closely associated with inferior patient survival. Together, these results indicate the importance of the balance between cytotoxic and regulatory pathways in the tumor microenvironment as a critical determinant of prognosis. This immune index also provides a framework for devising therapeutic strategies to enlarge the population of antitumor cytotoxic T cells and attenuate immune regulation. Among these approaches, vaccination with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) followed by antibody blockade of cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) provides clinical benefits for some advanced-course melanoma patients. The extent of tumor necrosis in post-treatment biopsies is linearly related to the natural logarithm of the ratio of CD 8(+) T cells to FoxP 3(+) Tregs. These findings show a concordance between the immune signature of tumor protection in endogenous and therapy-induced responses, strongly supporting Martin Mihm's original insights.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20482675      PMCID: PMC3905324          DOI: 10.1111/j.1600-0560.2010.01506.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  69 in total

Review 1.  The B7 family revisited.

Authors:  Rebecca J Greenwald; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 2.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self.

Authors:  Shimon Sakaguchi
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

3.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

Review 4.  Combinatorial cancer immunotherapy.

Authors:  F Stephen Hodi; Glenn Dranoff
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

5.  CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

Authors:  Sergio A Quezada; Karl S Peggs; Michael A Curran; James P Allison
Journal:  J Clin Invest       Date:  2006-06-15       Impact factor: 14.808

Review 6.  NF-kappaB: linking inflammation and immunity to cancer development and progression.

Authors:  Michael Karin; Florian R Greten
Journal:  Nat Rev Immunol       Date:  2005-10       Impact factor: 53.106

7.  Regulatory T cell lineage specification by the forkhead transcription factor foxp3.

Authors:  Jason D Fontenot; Jeffrey P Rasmussen; Luke M Williams; James L Dooley; Andrew G Farr; Alexander Y Rudensky
Journal:  Immunity       Date:  2005-03       Impact factor: 31.745

8.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

9.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.

Authors:  Gaynor J Bates; Stephen B Fox; Cheng Han; Russell D Leek; José F Garcia; Adrian L Harris; Alison H Banham
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

10.  Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.

Authors:  Ping Yu; Youjin Lee; Wenhua Liu; Thomas Krausz; Anita Chong; Hans Schreiber; Yang-Xin Fu
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

View more
  15 in total

Review 1.  Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.

Authors:  A Mitsuhashi; Y Okuma
Journal:  Clin Transl Oncol       Date:  2018-01-08       Impact factor: 3.405

Review 2.  Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment.

Authors:  Mizuki Nishino; Sree H Tirumani; Nikhil H Ramaiya; F Stephen Hodi
Journal:  Eur J Radiol       Date:  2015-03-23       Impact factor: 3.528

3.  Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.

Authors:  Tsubasa Miyazaki; Eiichi Ishikawa; Masahide Matsuda; Hiroyoshi Akutsu; Satoru Osuka; Noriaki Sakamoto; Shingo Takano; Tetsuya Yamamoto; Koji Tsuboi; Akira Matsumura
Journal:  J Neurooncol       Date:  2017-04-26       Impact factor: 4.130

4.  Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.

Authors:  Grit S Herter-Sprie; Shohei Koyama; Houari Korideck; Josephine Hai; Jiehui Deng; Yvonne Y Li; Kevin A Buczkowski; Aaron K Grant; Soumya Ullas; Kevin Rhee; Jillian D Cavanaugh; Neermala Poudel Neupane; Camilla L Christensen; Jan M Herter; G Mike Makrigiorgos; F Stephen Hodi; Gordon J Freeman; Glenn Dranoff; Peter S Hammerman; Alec C Kimmelman; Kwok-Kin Wong
Journal:  JCI Insight       Date:  2016-06-16

Review 5.  Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival.

Authors:  Michel Morre; Stéphanie Beq
Journal:  Target Oncol       Date:  2012-03-02       Impact factor: 4.493

6.  Immunological network signatures of cancer progression and survival.

Authors:  Trevor Clancy; Marco Pedicini; Filippo Castiglione; Daniele Santoni; Vegard Nygaard; Timothy J Lavelle; Mikael Benson; Eivind Hovig
Journal:  BMC Med Genomics       Date:  2011-03-31       Impact factor: 3.063

7.  Multiplex serum biomarker assessments: technical and biostatistical issues.

Authors:  Lisa H Butterfield; Douglas M Potter; John M Kirkwood
Journal:  J Transl Med       Date:  2011-10-11       Impact factor: 5.531

Review 8.  Cytokines: Signalling Improved Immunotherapy?

Authors:  Alana J De Luca; A Bruce Lyons; Andrew S Flies
Journal:  Curr Oncol Rep       Date:  2021-07-16       Impact factor: 5.075

9.  Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance.

Authors:  Douglas C Palmer; Geoffrey C Guittard; Zulmarie Franco; Joseph G Crompton; Robert L Eil; Shashank J Patel; Yun Ji; Nicholas Van Panhuys; Christopher A Klebanoff; Madhusudhanan Sukumar; David Clever; Anna Chichura; Rahul Roychoudhuri; Rajat Varma; Ena Wang; Luca Gattinoni; Francesco M Marincola; Lakshmi Balagopalan; Lawrence E Samelson; Nicholas P Restifo
Journal:  J Exp Med       Date:  2015-11-02       Impact factor: 14.307

10.  An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma.

Authors:  Felicity C Stark; Risini D Weeratna; Lise Deschatelets; Komal Gurnani; Renu Dudani; Michael J McCluskie; Lakshmi Krishnan
Journal:  Vaccines (Basel)       Date:  2017-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.